en · de · es · pt
handling-notes.peptides9000.com › Guide › Bremelanotide Identity And Background — Quick Reference

Bremelanotide Identity And Background — Quick Reference

By Editorial Desk · published 2025-07-27 · last reviewed 2025-09-12 · Guide

cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Bremelanotide Naming and Background

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Pt-141 at a glance

PropertyValueNotes
Molecular formulaC50H68N14O10Cyclic heptapeptide backbone
Molecular massApproximately 1025 DaNominal mass of the free peptide
AppearanceWhite to off-white lyophilised powderTypical for purified synthetic peptides
Solubility classFreely soluble in waterOrganic solubility is limited
Typical storage temperature−20 °C or belowProtect from moisture and light

Identity and Chemical Background

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Related pages on this site

Development History And Regulatory Status

PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.

Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.

Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.

Reference notes

Indications for the surgical treatment of aortic dissection include an acute proximal aortic dissection and an acute distal aortic dissection with one or more complications. Complications include compromise of a vital organ, rupture or impending rupture of the aorta, retrograde dissection into the ascending aorta. These are more common with a history of Marfan syndrome or Ehlers–Danlos syndrome. The objective in the surgical management of aortic dissection is to resect (remove) the most severely damaged segments of the aorta and to obliterate the entry of blood into the false lumen (both at the initial intimal tear and any secondary tears along the vessel). While excision of the intimal tear may be performed, it does not significantly change mortality. The particular treatment used depends on the segment or segments of the aorta involved. Some treatments are:

== Protein structure == The first structure of a creatine kinase solved by X-ray protein crystallography was that of the octameric, sarcomeric muscle-type mitochondrial CK (s-mtCK) in 1996., followed by the structure of ubiquitous mitochondrial CK (u-mtCK) in 2000. The atomic structure of the banana-shaped, dimeric cytosolic brain-type BB-CK was solved in 1999 at a resolution of 1,4 Å. Cytosolic BB-CK, as well as muscle-type MM-CK both form banana-shaped symmetric dimers, with one catalytic active site in each subunit.

The organisms the Calvin cycle is found in are plants, algae, cyanobacteria, aerobic proteobacteria, and purple bacteria. The Calvin cycle fixes carbon in the chloroplasts of plants and algae, and in the cyanobacteria. It also fixes carbon in the anoxygenic photosynthesis in one type of Pseudomonadota called purple bacteria, and in some non-phototrophic Pseudomonadota. Of the other autotrophic pathways, three are known only in bacteria (the reductive citric acid cycle, the 3-hydroxypropionate cycle, and the reductive glycine pathway), two only in archaea (two variants of the 3-hydroxypropionate cycle), and one in both bacteria and archaea (the reductive acetyl CoA pathway). Sulfur- and hydrogen-oxidizing bacteria often use the Calvin cycle or the reductive citric acid cycle.

Herpetic gingivostomatitis: A self-limiting viral infection which is caused by herpes simplex virus-1 (HSV-1). It usually presents in young children and is very contagious. It is characterised by the presence of small oral blisters which break down and coalesce into ulcers. Herpes labialis (cold sore): Reactivation of latent herpes simplex virus-1 triggered by sunlight, stress, and hormonal changes. It is characterised by the presence of crusting blisters on the upper lip. Chickenpox: A type of viral infection which is caused by varicella zoster virus and presents in children. Numerous itchy blisters are found on the face and body. Blisters could also be found on inner cheek and palate of the mouth. Herpes zoster/shingles: Viral infection caused by reactivation of latent varicella zoster virus and found in adults. Patients can present with acute pain before or after the onset of blisters. If viral reactivation occurs in the facial nerve, it can cause Ramsay–Hunt syndrome in which patients can develop facial paralysis, blisters around the ears and on the tongue, and loss of tongue sensation. Hand, foot, and mouth disease: A highly contagious viral infection which infects young children and is caused by coxsackie virus A16. It is characterised by presence of small blisters all over the limbs and the mouth. Measles: A highly infectious condition which is caused by measles virus. It most commonly presents in young children who have not been vaccinated. It is characterised by presence of white spots (Koplik's spots) which rupture to form ulcers on the palate.

Sources: en.wikipedia.org

Reference notes

This helped the SENSEX crossed 7,000 points for the first time. 8000, 8 September 2005 – On 8 September 2005, the Bombay Stock Exchange's benchmark 30-share index – the SENSEX – crossed the 8,000 level following brisk buying by foreign and domestic funds in early trading. 9000, 9 December 2005 – The SENSEX on 28 November 2005 crossed 9,000 and touched a peak of 9,000.32 points during mid-session at the Bombay Stock Exchange on the back of frantic buying spree by foreign institutional investors and well supported by local operators as well as retail investors. However, it was on 9 December 2005 that the SENSEX first closed at over 9,000 points. 10,000, 7 February 2006 – The SENSEX on 6 February 2006 touched 10,003 points during mid-session. The SENSEX finally closed above the 10,000 mark on 7 February 2006. 20,000, 11 December 2007 – The SENSEX on 29 October 2007 crossed the 20,000 mark for the first time during intra-day trading, but closed at 19,977.67 points. However, it was on 11 December 2007 that it finally closed at a figure above 20,000 points on the back of aggressive buying by funds. 21,000, 5 November 2010 – The SENSEX on 8 January 2008 crossed the 21,000 mark for the first time, reaching an intra-day peak of 21,078 points, before closing at 20,873. However, it was not until 5 November 2010 that the SENSEX closed at 21,004.96, for its first close above 21,000 points. This record would stand for nearly three years, until 30 October 2013, when the SENSEX closed at 21,033.97 points.

Since then, sulfur has typically been produced from petroleum, natural gas, and related fossil resources, from which it is obtained mainly as hydrogen sulfide. Organosulfur compounds, undesirable impurities in petroleum, may be upgraded by subjecting them to hydrodesulfurization, which cleaves the C–S bonds:

Six days after the attacks, President Bush made a public appearance at Washington, D.C.'s largest Islamic Center where he acknowledged the "incredibly valuable contribution" of American Muslims and called for them "to be treated with respect." Numerous incidents of harassment and hate crimes against Muslims and South Asians were reported in the days following the attacks. Sikhs were also targeted due to their use of turbans, which are stereotypically associated with Muslims. There were reports of attacks on mosques and other religious buildings (including the firebombing of a Hindu temple), and assaults on individuals, including one murder: Balbir Singh Sodhi, a Sikh mistaken for a Muslim, who was fatally shot on September 15, 2001, in Mesa, Arizona. Two dozen members of Osama bin Laden's family were urgently evacuated out of the country on a private charter plane under FBI supervision three days after the attacks. According to an academic study, people perceived to be Middle Eastern were as likely to be victims of hate crimes as followers of Islam during this time. The study also found a similar increase in hate crimes against people who may have been perceived as Muslims, Arabs, and others thought to be of Middle Eastern origin. A report by the South Asian American advocacy group South Asian Americans Leading Together documented media coverage of 645 bias incidents against Americans of South Asian or Middle Eastern descent between September 11 and 17, 2001. Crimes such as vandalism, arson, assault, shootings, harassment, and threats in numerous places were documented.

Sources: en.wikipedia.org

Notes from published material

== History == In 1995, a study by the National Institute of Neurological Disorders and Stroke showed the effectiveness of administering intravenous alteplase to treat ischemic stroke. This sparked a medical paradigm shift as it redesigned stroke treatment in the emergency department to allow for timely assessment and therapy for ischemic stroke patients.

=== Story === The player follows Angela's journey toward the "one perfect book" in the Library from the view of Roland, a Fixer who becomes her servant after trespassing into the Library uninvited. The story is broken up into various chapters. As Roland's past is gradually shed light on and Angela comes closer to becoming human, the Library becomes an ever-growing threat to the City, urging the Associations (organized groups of fixers, often centered around a single theme) to take action. Argalia, a mysterious Fixer known as the "Blue Reverberation" recruits various characters into a group known as the "Reverberation Ensemble" for an unknown cause, culminating in them breaking into the Library, scattering to the ten floors to claim the Light for their greatest performance that will overturn the City. The Library ultimately emerges victorious after a hard-fought battle. Just as Angela finally gains a human body, Roland betrays Angela and reveals his true motive for coming to the Library: to make her suffer as revenge for her actions instigating the Distortion phenomenon and indirectly causing the death of his wife Angelica, a former Color Fixer known as the "Black Silence". Roland ultimately fails to defeat the Library and pleads for Angela to kill him, or he will kill her if she falters. If all of Angela's Floor realizations have not been completed, she will kill Roland and the Librarians and obtain the one true book.

Like all members of the Loxosceles genus, the brown recluse has potent tissue-destroying venoms containing the dermonecrotic agent sphingomyelinase D. Most bites are minor with no dermonecrosis, but a small number of brown recluse bites produce loxoscelism, a condition where the skin around the bite dies. While loxoscelism usually manifests as a skin condition (cutaneous loxoscelism), it can also include systemic symptoms like fever, nausea, and vomiting (viscerocutaneous loxoscelism). In very rare cases, bites can even cause hemolysis – the bursting of red blood cells. In one study of clinically diagnosed brown recluse bites, skin necrosis occurred 37% of the time, while systemic illness occurred 14% of the time. As suggested by its specific name reclusa (recluse), the brown recluse spider is rarely aggressive, and bites from the species are uncommon. In 2001, more than 2,000 brown recluse spiders were removed from a heavily infested home in Kansas, yet the four residents who had lived there for years were never harmed by the spiders, despite many encounters with them. The spider usually bites only when pressed against the skin, such as when tangled within clothes, shoes, towels, bedding, or inside work gloves. Many human victims report having been bitten after putting on clothes or shoes that had not been worn recently or had been left for many days undisturbed on the floor. The fangs of the brown recluse are not large enough to penetrate most fabric.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is this?

It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.

Why does the code PT-141 still appear?

PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.

Is intranasal use equivalent to approved use?

No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.

What does the code PT-141 designate?

PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.

Network